Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment

Publication
Video
Special ReportsBreast Cancer (Issue 2)
Volume 1
Issue 2

William Sikov, MD, associate director of Clinical Research, Program in Women

William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.

Recent Videos
3 KOLs are featured in this series.
Related Content